Research articlePublished 26 Sep 2018
Efficacy and safety of pemetrexed and cisplatin chemotherapy as first line in advanced stage of lung adenocarcinoma.
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Pemetrexed is a newer antifolate drug that has multiple intracellular targets. Clinical trials of Pemetrexed in advanced nonsmall cell lung carcinoma (NSCLC) setting have demonstrated beneficial outcomes. This study evaluated the efficacy and safety of Pemetrexed and Cisplatin combination as first line in advanced stage NSCLC adenocarcinoma patients. Methods: This was a prospective study conducted on previously untreated 50 patients with NSCLC (adenocarcinoma) of stage III B and IV disease. Patients received Pemetrexed 500 mg/m2 and Cisplatin 75 mg/m2 on day 1 of every 21-day cycle for a total of 6 cycles. Tumor response was calculated after 3 cycles and 6 cycles as per RECIST criteria version 1.1. Toxicity and adverse events (AEs) were assessed as per Common Terminology Criteria for Adverse Events (CTCAE) version 3. Results: The tumor response rate after 6 cycles of chemotherapy was as follows: 12% (6) patients had complete response, 48% (24) had a partial response, and 22% (11) stable disease. The overall response rate was 60% and the clinical benefit rate was 82%. Out of total patients, hematological toxicity in the form grade 3/4 granulocytopenia was seen in 20 (40%) patients, followed grade 3/4 leukopenia 12 (24%), grade 3/4 anaemia in 5 (10%) and grade 3/4 thrombocytopenia in 5(10%). Whereas nonhematological toxicity was comparatively less in the form of grade 3 vomiting in 2 (4%) patients. Over all this combination was well tolerated. Conclusion: Pemetrexed and Cisplatin chemotherapy combination was found to be efficacious and was well tolerated in advanced NSCLC adenocarcinoma patients.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Molecular Oncology Research
- SubjectOncology & Cancer
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Kartikeya Jain”
- BylineArticles whose byline prints “Ajay Bapna”
- BylineArticles whose byline prints “Naresh Somani”
- BylineArticles whose byline prints “Lalit Mohan Sharma”
- BylineArticles whose byline prints “Pawan Aggarwal”
